BioSpace News Archive

NANOBIOTIX announced the first patient in the United States has been randomized in NANORAY-312, a global Phase 3 registrational trial evaluating NBTXR3 for the treatment of elderly patients with locally advanced head and neck squamous cell carcinoma who are ineligible for platinum-based chemotherapy.

SpringWorks Therapeutics, Inc. announced that the Company has completed the submission of a New Drug Application to the United States Food and Drug Administration for nirogacestat, an investigational gamma secretase inhibitor, for the treatment of adults with desmoid tumors.

ZielBio, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead program, ZB131, for the treatment of treatment of pancreatic cancer, a rare solid-tumor cancer originating from the pancreas.

Novocure announced it will participate in the 41st Annual J. P. Morgan Healthcare Conference on January 10-11, 2023.

ALR Technologies SG Ltd., the diabetes management company, announced the completion of a long-term manufacturing and supply agreement with Infinovo Medical Co. Ltd for the Continuous Glucose Monitor hardware used in the GluCurve Pet CGM.

PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company announced that they have entered into a Research Collaboration and License Agreement with US-based Eli Lilly and Company focused on the discovery and development of novel peptide drug conjugates.

Adaptive Biotechnologies Corporation announced it will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company announced topline study results from its Phase 2 investigational trial with CNM-ZnAg, an ionic solution of zinc and silver, for the treatment of non-hospitalized acutely symptomatic participants infected with COVID-19.

Gilead Sciences, Inc. and Jounce Therapeutics, Inc. amended their existing license agreement for GS-1811, enabling Gilead to buy out remaining contingent payments potentially due under the license agreement executed in August 2020.

Tiziana Life Sciences Ltd, a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases announces its interim results for the six months ended 30 June 2022.